Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?

This study presents the chemo-immunotherapy experience in patients with relapsed/progressive high-risk neuroblastoma treated within the off-label use program of the Neuroblastoma Committee of the French Society of Pediatric Oncology (SFCE).

Source: European Journal of Cancer - March 11, 2024 Category: Cancer & Oncology Authors: Patricia Raiser, Gudrun Schleiermacher, Marion Gambart, Benoit Dumont, Anne-Sophie Defachelles, Estelle Thebaud, Julie Tandonnet, Claudia Pasqualini, St éphanie Proust, Natacha Entz-Werle, Isabelle Aerts, Lee A. Ndounga-Diakou, Arnaud Petit, Chloe Puiseu Tags: Original Research Source Type: research